Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.

@article{Curry2017DiverseTO,
  title={Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.},
  author={Jonathan L Curry and Michael T Tetzlaff and Priyadharsini Nagarajan and Carol R Drucker and Adi Diab and Sharon R Hymes and Madeleine Duvic and W J Hwu and Jennifer A Wargo and Carlos A Torres-Cabala and Ronald P. Rapini and Victor G Prieto},
  journal={Journal of cutaneous pathology},
  year={2017},
  volume={44 2},
  pages={158-176}
}
Immunomodulatory drugs that leverages host immune mechanisms to destroy tumor cells have been met with great promise in the treatment of cancer. Immunotherapy, targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1) have shown tremendous improvements in the survival of patients with advanced solid tumors. However, the development of dermatologic toxicity (DT) is a consequence to immunotherapy. Review of published… CONTINUE READING
Highly Cited
This paper has 20 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 18 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…